Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review
<b>Background/Objectives</b>: To conduct a systematic review to evaluate the detection rates (DR) of the three FDA-approved PSMA-targeted radiopharmaceuticals in patients with recurrent prostate cancer. <b>Methods</b>: Two individuals systematically searched MEDLINE, ScienceD...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/10/1224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327419033387008 |
|---|---|
| author | Soroush Rais-Bahrami Phillip Davis Albert Chau Samuel J. Galgano Brian F. Chapin David M. Schuster Catriona M. Turnbull |
| author_facet | Soroush Rais-Bahrami Phillip Davis Albert Chau Samuel J. Galgano Brian F. Chapin David M. Schuster Catriona M. Turnbull |
| author_sort | Soroush Rais-Bahrami |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: To conduct a systematic review to evaluate the detection rates (DR) of the three FDA-approved PSMA-targeted radiopharmaceuticals in patients with recurrent prostate cancer. <b>Methods</b>: Two individuals systematically searched MEDLINE, ScienceDirect, and Cochrane Libraries (February 2025), and independently reviewed all results to identify studies reporting patient-level <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-DCFPyL, or <sup>18</sup>F-flotufolastat DR in ≥100 evaluable patients with recurrent prostate cancer. Sample-weighted means (SWM) of extracted DR were calculated. <b>Results</b>: Of 5059 published articles, 37 met our inclusion criteria, reporting data from 8843 patients undergoing <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 27), <sup>18</sup>F-DCFPyL (<i>n</i> = 8), or <sup>18</sup>F-flotufolastat (<i>n</i> = 2) studies. Heterogeneity was noted across enrolled populations, particularly in prior treatments. <sup>68</sup>Ga-PSMA-11 studies recruited patients with marginally higher median PSA than <sup>18</sup>F-DCFPyL or <sup>18</sup>F-flotufolastat studies (median PSA ranged from 0.1 to 10.7, 0.2–2.5, and 0.6–1.1, respectively). Reported overall DR ranged from 25 to 91% for <sup>68</sup>Ga-PSMA-11, 49–86% for <sup>18</sup>F-DCFPyL, and 73–83% for <sup>18</sup>F-flotufolastat, with SWM of 71%, 66%, and 79%, respectively. Post-prostatectomy DR were reported in 18 articles, resulting in SWM DR of 58% for <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 12), 55% for <sup>18</sup>F-DCFPyL (<i>n</i> = 4), and 76% for <sup>18</sup>F-flotufolastat (<i>n</i> = 2). Among post-radiotherapy patients, SWM were 87% for <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 4), 90% for <sup>18</sup>F-DCFPyL (<i>n</i> = 2), and 99% for <sup>18</sup>F-flotufolastat (<i>n</i> = 1). SWM DR at PSA < 1 ng/mL were 53%, 42%, and 66% for <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 13), <sup>18</sup>F-DCFPyL (<i>n</i> = 5), and <sup>18</sup>F-flotufolastat (<i>n</i> = 2), respectively. <b>Conclusions</b>: Considerable heterogeneity exists across populations in studies of diagnostic PET radiopharmaceuticals. Despite a paucity of <sup>18</sup>F-DCFPyL and <sup>18</sup>F-flotufolastat studies compared with <sup>68</sup>Ga-PSMA-11, the available data suggest that all three radiopharmaceuticals provide high overall DR in patients with biochemical recurrence of prostate cancer. |
| format | Article |
| id | doaj-art-ba9b3f996e0942adad3a1fcfd7112cd3 |
| institution | Kabale University |
| issn | 2075-4418 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-ba9b3f996e0942adad3a1fcfd7112cd32025-08-20T03:47:53ZengMDPI AGDiagnostics2075-44182025-05-011510122410.3390/diagnostics15101224Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic ReviewSoroush Rais-Bahrami0Phillip Davis1Albert Chau2Samuel J. Galgano3Brian F. Chapin4David M. Schuster5Catriona M. Turnbull6Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35294, USABlue Earth Diagnostics Inc., Needham, MA 02494, USABlue Earth Diagnostics Ltd., Oxford OX4 4GA, UKDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADivision of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USABlue Earth Diagnostics Ltd., Oxford OX4 4GA, UK<b>Background/Objectives</b>: To conduct a systematic review to evaluate the detection rates (DR) of the three FDA-approved PSMA-targeted radiopharmaceuticals in patients with recurrent prostate cancer. <b>Methods</b>: Two individuals systematically searched MEDLINE, ScienceDirect, and Cochrane Libraries (February 2025), and independently reviewed all results to identify studies reporting patient-level <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-DCFPyL, or <sup>18</sup>F-flotufolastat DR in ≥100 evaluable patients with recurrent prostate cancer. Sample-weighted means (SWM) of extracted DR were calculated. <b>Results</b>: Of 5059 published articles, 37 met our inclusion criteria, reporting data from 8843 patients undergoing <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 27), <sup>18</sup>F-DCFPyL (<i>n</i> = 8), or <sup>18</sup>F-flotufolastat (<i>n</i> = 2) studies. Heterogeneity was noted across enrolled populations, particularly in prior treatments. <sup>68</sup>Ga-PSMA-11 studies recruited patients with marginally higher median PSA than <sup>18</sup>F-DCFPyL or <sup>18</sup>F-flotufolastat studies (median PSA ranged from 0.1 to 10.7, 0.2–2.5, and 0.6–1.1, respectively). Reported overall DR ranged from 25 to 91% for <sup>68</sup>Ga-PSMA-11, 49–86% for <sup>18</sup>F-DCFPyL, and 73–83% for <sup>18</sup>F-flotufolastat, with SWM of 71%, 66%, and 79%, respectively. Post-prostatectomy DR were reported in 18 articles, resulting in SWM DR of 58% for <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 12), 55% for <sup>18</sup>F-DCFPyL (<i>n</i> = 4), and 76% for <sup>18</sup>F-flotufolastat (<i>n</i> = 2). Among post-radiotherapy patients, SWM were 87% for <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 4), 90% for <sup>18</sup>F-DCFPyL (<i>n</i> = 2), and 99% for <sup>18</sup>F-flotufolastat (<i>n</i> = 1). SWM DR at PSA < 1 ng/mL were 53%, 42%, and 66% for <sup>68</sup>Ga-PSMA-11 (<i>n</i> = 13), <sup>18</sup>F-DCFPyL (<i>n</i> = 5), and <sup>18</sup>F-flotufolastat (<i>n</i> = 2), respectively. <b>Conclusions</b>: Considerable heterogeneity exists across populations in studies of diagnostic PET radiopharmaceuticals. Despite a paucity of <sup>18</sup>F-DCFPyL and <sup>18</sup>F-flotufolastat studies compared with <sup>68</sup>Ga-PSMA-11, the available data suggest that all three radiopharmaceuticals provide high overall DR in patients with biochemical recurrence of prostate cancer.https://www.mdpi.com/2075-4418/15/10/1224biochemical recurrenceprostate cancer imagingprostate specific membrane antigenpositron emission tomography |
| spellingShingle | Soroush Rais-Bahrami Phillip Davis Albert Chau Samuel J. Galgano Brian F. Chapin David M. Schuster Catriona M. Turnbull Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review Diagnostics biochemical recurrence prostate cancer imaging prostate specific membrane antigen positron emission tomography |
| title | Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review |
| title_full | Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review |
| title_fullStr | Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review |
| title_full_unstemmed | Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review |
| title_short | Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review |
| title_sort | detection rates of psma pet radiopharmaceuticals in recurrent prostate cancer a systematic review |
| topic | biochemical recurrence prostate cancer imaging prostate specific membrane antigen positron emission tomography |
| url | https://www.mdpi.com/2075-4418/15/10/1224 |
| work_keys_str_mv | AT soroushraisbahrami detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview AT phillipdavis detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview AT albertchau detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview AT samueljgalgano detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview AT brianfchapin detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview AT davidmschuster detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview AT catrionamturnbull detectionratesofpsmapetradiopharmaceuticalsinrecurrentprostatecancerasystematicreview |